Showing 1 posts of 1 posts found.
VIVES Partners, the managing company of VIVES Funds, has announced that it will contribute to an €84m Series B financing …
Long-acting therapies set to reshape HIV treatment market
MHRA authorises Lynkuet for hot flushes linked to breast cancer therapy
MHRA approves Romvimza for tenosynovial giant cell tumour
NICE recommends allergy immunotherapy tablets for younger children
Dunbar Pharmaceuticals and IPS Pharma announce distribution agreement